Surveillance Imaging Schedule for Stage II MSI-High Colon Cancer with BRAF Mutation
For stage II colon cancer that is MSI-high with a BRAF mutation, you should use a less intensive surveillance imaging schedule—specifically, annual CT scans of chest and abdomen for 3 years only, rather than more frequent imaging, because these patients have an excellent prognosis and intensive surveillance provides minimal survival benefit.
Risk Stratification Context
Stage II MSI-high colon cancer represents a favorable prognostic subgroup with excellent outcomes after curative resection 1. The presence of a BRAF mutation in this context does not carry the same poor prognosis as BRAF-mutant microsatellite stable (MSS) tumors 2. Research specifically addressing this molecular subtype suggests that intensive follow-up strategies offer minimal survival benefit for patients with good baseline prognosis 3, 4.
Recommended Surveillance Protocol
Cross-Sectional Imaging
- CT chest and abdomen: Annually for 3 years 1
- No imaging beyond 3 years unless clinically indicated
- PET scans are not recommended for routine surveillance 1
Rationale: Recent evidence demonstrates that MSI-high stage II patients have favorable overall survival (87.97%) and disease-free survival (81.92%) at 7 years, with no significant difference between intensive versus less intensive CT surveillance strategies 4. More frequent CT intervals (every 6 months versus annually) showed no survival advantage in this molecular subgroup 4.
Clinical Follow-Up
- History, physical examination, and CEA testing: Every 3-6 months for 5 years 1
- Given the favorable prognosis of MSI-high stage II disease, testing at the less frequent end (every 6 months) is appropriate 1
- Focus on new persistent symptoms that could indicate recurrence
Colonoscopy Surveillance
- First colonoscopy: 1 year after surgery 1
- Subsequent colonoscopies: Every 5 years if normal 1
- Important caveat for MSI-high patients: Consider more frequent colonoscopy in the first 2 years (at 6 months post-surgery, then 13-24 months after first polyp detection) because 39.75% of MSI-high patients develop polyps during follow-up, with the highest detection rate (32.81%) occurring 0-6 months after surgery 4
Key Clinical Pitfalls to Avoid
1. Over-Surveillance Trap
Do not apply intensive imaging protocols designed for high-risk patients to this favorable molecular subgroup. The 2016 US Multi-Society Task Force guidelines note that 80% of recurrences occur within 2-2.5 years and 95% by 5 years 1, but MSI-high stage II patients have substantially lower recurrence rates overall 4.
2. BRAF Mutation Misinterpretation
The poor prognosis associated with BRAF V600E mutations applies primarily to MSS tumors 2, 3. In MSI-high tumors, the BRAF mutation does not confer the same adverse outcome. Research indicates that locally advanced colorectal cancer patients with BRAF-V600E mutations in the MSS context have poor survival after recurrence, making intensive surveillance less beneficial 3—but this does not apply to your MSI-high patient.
3. Inadequate Lymph Node Assessment
Ensure adequate lymph node dissection (≥12 nodes) was performed at surgery. Inadequate nodal assessment (<12 nodes) is an independent adverse prognostic factor that may warrant consideration of more intensive surveillance 5. If nodal assessment was inadequate, consider imaging at the more frequent end of the range (every 6-12 months for 3 years) 1.
Evidence Quality and Nuances
The recommendations are based on moderate-quality guideline evidence from ASCO 2013 1 and the 2016 US Multi-Society Task Force 6, augmented by recent research specifically addressing MSI-high surveillance 4.
Important divergence in the evidence: While general guidelines recommend annual CT for 3 years for stage II disease 1, the most recent 2025 research on MSI-high patients suggests even less intensive CT surveillance may be acceptable (intervals >1 year) given the excellent prognosis 4. However, until this is validated in prospective trials, annual CT for 3 years remains the standard recommendation.
The evidence shows that intensive multimodality surveillance improves overall survival primarily through detection of resectable recurrences 6, but this benefit is most apparent in higher-risk patients. For MSI-high stage II disease, the absolute benefit is minimal given the low baseline recurrence risk.
When to Omit Surveillance
If your patient has severe comorbid conditions that would preclude surgical resection or systemic therapy for recurrence, surveillance imaging should not be performed 1. Surveillance is only justified when early detection would lead to aggressive curative-intent treatment.